🎉 M&A multiples are live!
Check it out!

Viking Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Viking Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Viking Therapeutics Overview

About Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.


Founded

2012

HQ

United States of America
Employees

36

Financials

LTM Revenue $0.4M

LTM EBITDA -$163M

EV

$1.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Viking Therapeutics Financials

Viking Therapeutics has a last 12-month revenue of $0.4M and a last 12-month EBITDA of -$163M.

In the most recent fiscal year, Viking Therapeutics achieved revenue of n/a and an EBITDA of -$151M.

Viking Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Viking Therapeutics valuation multiples based on analyst estimates

Viking Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$101M -$151M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$68.9M -$85.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Viking Therapeutics Stock Performance

As of April 15, 2025, Viking Therapeutics's stock price is $25.

Viking Therapeutics has current market cap of $2.8B, and EV of $1.9B.

See Viking Therapeutics trading valuation data

Viking Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.9B $2.8B XXX XXX XXX XXX $-1.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Viking Therapeutics Valuation Multiples

As of April 15, 2025, Viking Therapeutics has market cap of $2.8B and EV of $1.9B.

Viking Therapeutics's trades at 4132.4x LTM EV/Revenue multiple, and -11.4x LTM EBITDA.

Analysts estimate Viking Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Viking Therapeutics and 10K+ public comps

Viking Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.9B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -12.3x XXX XXX XXX
P/E -25.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -21.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Viking Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Viking Therapeutics Valuation Multiples

Viking Therapeutics's NTM/LTM revenue growth is 588%

Viking Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $4.2M for the same period.

Over next 12 months, Viking Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Viking Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Viking Therapeutics and other 10K+ public comps

Viking Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 50% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $4.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Viking Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Viking Therapeutics M&A and Investment Activity

Viking Therapeutics acquired  XXX companies to date.

Last acquisition by Viking Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Viking Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Viking Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Viking Therapeutics

When was Viking Therapeutics founded? Viking Therapeutics was founded in 2012.
Where is Viking Therapeutics headquartered? Viking Therapeutics is headquartered in United States of America.
How many employees does Viking Therapeutics have? As of today, Viking Therapeutics has 36 employees.
Who is the CEO of Viking Therapeutics? Viking Therapeutics's CEO is Dr. Brian Lian, PhD.
Is Viking Therapeutics publicy listed? Yes, Viking Therapeutics is a public company listed on NAS.
What is the stock symbol of Viking Therapeutics? Viking Therapeutics trades under VKTX ticker.
When did Viking Therapeutics go public? Viking Therapeutics went public in 2015.
Who are competitors of Viking Therapeutics? Similar companies to Viking Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Viking Therapeutics? Viking Therapeutics's current market cap is $2.8B
What is the current revenue of Viking Therapeutics? Viking Therapeutics's last 12-month revenue is $0.4M.
What is the current EBITDA of Viking Therapeutics? Viking Therapeutics's last 12-month EBITDA is -$163M.
What is the current EV/Revenue multiple of Viking Therapeutics? Current revenue multiple of Viking Therapeutics is 4132.4x.
What is the current EV/EBITDA multiple of Viking Therapeutics? Current EBITDA multiple of Viking Therapeutics is -11.4x.
Is Viking Therapeutics profitable? Yes, Viking Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.